Cellyan Biotechnology Co., Ltd
Cellyan Biotechnology Co., Ltd is a Hong Kong-based biotechnology and pharmaceutical services company focused on over-the-counter pharmaceutical cross-border commerce. The company provides OTC pharmaceutical procurement and distribution, along with e-commerce supply chain services that support merchants handling cross-border healthcare products. Its operating activities also include customs clearance, drug registration support, warehousing, packaging, and delivery logistics, forming an integrated service platform for the movement of OTC medicines across Hong Kong and Mainland China. Cellyan Biotechnology Co., Ltd serves the pharmaceutical trade, e-commerce, and logistics segments by linking suppliers, distributors, and online merchants through a coordinated supply chain model. Its Class A Ordinary Shares represent the company’s equity in the public market and are associated with a business centered on regulated pharmaceutical distribution and cross-border fulfillment services.
$0.11
+$0.00 (+0.00%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-7.47% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 33.9% YoY. Margins deteriorated 8.5pp alongside, both lines moving the wrong way.
Free cash flow declined 292% versus the prior year, cash generation momentum has weakened. ROIC dropped from 1.46% to -8.71%, capital efficiency is deteriorating.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$13M
▼ -33.9% YoY
Net Income (TTM)
-$1M
▼ -4098.6% YoY
Op. Margin
-7.47%
▼ -8.5pp YoY
ROIC
-8.71%
▼ -10.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$794K
▼ -291.7% YoY
Op. Cash Flow (TTM)
-$752K
▼ -232.0% YoY
Net Debt
$1M
Cash & Equiv.
$222K
3Y CAGR: +2.3%
Continue Research
Is Cellyan Biotechnology Co. (HKPD) overvalued?
Cellyan Biotechnology Co. (HKPD)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Cellyan Biotechnology Co. scores 18/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Cellyan Biotechnology Co. a high-quality business?+
Cellyan Biotechnology Co. scores 18 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -7.5% operating margin and a -8.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Cellyan Biotechnology Co. a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh HKPD's valuation and scores 18/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Medical Distribution
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.